Find your PDFs fast.
Welcome to the Pubget Medical Subject Headings (MESH) browser. Click on a topic or subtopic below to explore related papers. In the gold box is the most recent paper about the current MESH term, and below are 20 related papers.
Blood Component Removal (4):
Recent article
Blood Component Removal
Circulation (124)8 2011
Abstract
We first show that negatively charged dextran sulfate cellulose columns adsorb sFlt-1 in vitro. In 5 women with very preterm preeclampsia and elevated circulating sFlt-1 levels, we next demonstrate that a single dextran sulfate cellulose apheresis treatment reduces circulating sFlt-1 levels in a dos...
|
PMID: 21810665
PDF is available here.
PDF is available here.
| < More recent | Older article > |
Abstract
Hemolytic-uremic syndrome (HUS) is a disease that can lead to acute kidney injury and often to other serious sequelae, including death. The disease is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. In view of the different courses of HU...
|
PMID: 21272247
PDF is available here.
PDF is available here.
Nippon Jinzo Gakkai shi (53)1 2011
Abstract
We diagnosed a focal segmental glomerulosclerosis collapsing variant. After steroid pulse therapy and LDL apheresis, his serum Cre level had decreased to 1.1 mg/dL and the urinary protein level to 2.5 g/gCr. Patients with a focal segmental glomerulosclerosis collapsing variant are poor responders to...
|
PMID: 21370578
PDF is available here.
PDF is available here.
New Zealand Medical Journal (123)1319 2010
Abstract
Abstract
Abstract
Abstract
Abstract
Abstract
Abstract
Abstract
Abstract
Abstract
Abstract
Abstract
Abstract
We tested the hypothesis that LDL apheresis would reduce the plasma levels of apoE4. We analyzed the plasma apoE4 levels using enzyme-linked immunosorbent assay immediately before and after LDL apheresis in 10 patients with familial hypercholesterolemia who had tested positive for the apoE4 isoform....
|
PMID: 20494666
PDF is available here.
PDF is available here.
Abstract
The purpose of establishing the RheoNet registry was to evaluate the safety and efficacy of rheopheresis, a specific method of therapeutic apheresis used to treat microcirculatory disorders. Apheresis centers providing rheopheresis therapy and physicians caring for the underlying disease were asked...
|
PMID: 20609179
PDF is available here.
PDF is available here.
Vox Sanguinis (98)4 2010
Abstract
Georgian medical news ()182 2010
Abstract
The goal of the research was to study the mechanisms of the regulation of deformability of RBCs in various aged people. Morphological, biophysical and biochemical parameters of RBCs were studied in 50 practically healthy men - volunteers (divided in two age groups: adults (22-30 years old), and old...
|
PMID: 20587832
PDF is available here.
PDF is available here.
Abstract
Six of the patients underwent at least one session of GCAP. Three of the patients had coexistent renal failure and five of the six patients were corticosteroid nonresponders. All patients tolerated the procedure. However, three of the patients died during their hospital admission within 4 days of GC...
|
PMID: 19855284
PDF is available here.
PDF is available here.
MMW Fortschritte der Medizin (152)13 2010
Abstract
Abstract
Hemapheresis is made up of a set of essential methods for modern medical practices. Applicated to donors, they allow production of labile blood products as well as raw material for plasma products industrial manufacturing; applicated to patients, they are indispensable for the treatment of many path...
|
PMID: 20674436
PDF is available here.
PDF is available here.
Transfusion (50)4 2010
Abstract
Transfusion (50)4 2010
Abstract
Plasma proteins demonstrated different sensitivities to riboflavin and UV treatment. The amount of total protein remained unchanged. After treatment, fibrinogen (antigen) showed 99% retention; Factor (F)XII, FXIII, ADAMTS-13, and von Willebrand factor (ristocetin cofactor) 96% to 100%. Fibrinogen re...
|
PMID: 20051060
PDF is available here.
PDF is available here.
Vox Sanguinis (98)2 2010
Abstract
The Mirasol Pathogen Reduction Technology System (PRT) for Plasma (CaridianBCT) is based on a riboflavin and UV light treatment process resulting in pathogen inactivation due to irreversible, photochemically induced damage of nucleic acids. This study evaluated the in vitro protein q...
|
PMID: 19719460
PDF is available here.
PDF is available here.
Vox Sanguinis (98)2 2010
Abstract
The Mirasol Pathogen Reduction Technology System (PRT) for Plasma (CaridianBCT) is based on a riboflavin and UV light treatment process resulting in pathogen inactivation due to irreversible, photochemically induced damage of nucleic acids. This study evaluated the in vitro protein q...
|
PMID: 19719460
PDF is available here.
PDF is available here.
Vox Sanguinis (98)2 2010
Abstract
The Mirasol Pathogen Reduction Technology System (PRT) for Plasma (CaridianBCT) is based on a riboflavin and UV light treatment process resulting in pathogen inactivation due to irreversible, photochemically induced damage of nucleic acids. This study evaluated the in vitro protein q...
|
PMID: 19719460
PDF is available here.
PDF is available here.
Vox Sanguinis (98)2 2010
Abstract
The Mirasol Pathogen Reduction Technology System (PRT) for Plasma (CaridianBCT) is based on a riboflavin and UV light treatment process resulting in pathogen inactivation due to irreversible, photochemically induced damage of nucleic acids. This study evaluated the in vitro protein q...
|
PMID: 19719460
PDF is available here.
PDF is available here.
Vox Sanguinis (98)2 2010
Abstract
The Mirasol Pathogen Reduction Technology System (PRT) for Plasma (CaridianBCT) is based on a riboflavin and UV light treatment process resulting in pathogen inactivation due to irreversible, photochemically induced damage of nucleic acids. This study evaluated the in vitro protein q...
|
PMID: 19719460
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
With buffy coat (BC) processing of whole blood (WB) donations, the preparation of plasma occurs within 24 hours rather than 8 hours of collection. The effect of this change on coagulation factor function in plasma and cryoprecipitate was evaluated during the validation of this produc...
|
PMID: 19843287
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.
Transfusion (50)2 2010
Abstract
The Spectra Optia (SPO; CaridianBCT) is a new apheresis device based on the COBE Spectra (CSP; CaridianBCT) platform. This study was designed to evaluate the safety and efficiency of the SPO in comparison to the predicate CSP device.
Twenty patients were recruited for...
|
PMID: 19804570
PDF is available here.
PDF is available here.